IMD 1041

Drug Profile

IMD 1041

Alternative Names: IMD-1041

Latest Information Update: 28 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Medicinal Molecular Design
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 May 2013 IMD 1041 is available for licensing as of 28 May 2013. http://www.immd.co.jp
  • 28 May 2013 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top